Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(3.76)
# 676
Out of 4,855 analysts
12
Total ratings
50%
Success rate
12.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PYPD PolyPid | Initiates: Buy | $9 | $3.27 | +175.23% | 1 | Jun 5, 2025 | |
| CING Cingulate | Maintains: Buy | $12 → $11 | $4.36 | +152.29% | 2 | May 19, 2025 | |
| CRVO CervoMed | Maintains: Buy | $15 → $20 | $7.62 | +162.47% | 3 | Mar 18, 2025 | |
| VRNA Verona Pharma | Initiates: Buy | $68 | $84.34 | -19.37% | 1 | Jan 10, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Initiates: Buy | $7 | $0.82 | +752.10% | 1 | Jan 10, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 | $1.92 | +264.58% | 2 | Dec 24, 2024 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $8.35 | +247.31% | 1 | Dec 5, 2024 | |
| LGVN Longeveron | Initiates: Buy | $10 | $1.23 | +713.01% | 1 | Dec 5, 2024 |
PolyPid
Jun 5, 2025
Initiates: Buy
Price Target: $9
Current: $3.27
Upside: +175.23%
Cingulate
May 19, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $4.36
Upside: +152.29%
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $7.62
Upside: +162.47%
Verona Pharma
Jan 10, 2025
Initiates: Buy
Price Target: $68
Current: $84.34
Upside: -19.37%
Reviva Pharmaceuticals Holdings
Jan 10, 2025
Initiates: Buy
Price Target: $7
Current: $0.82
Upside: +752.10%
Gain Therapeutics
Dec 24, 2024
Maintains: Buy
Price Target: $7
Current: $1.92
Upside: +264.58%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $8.35
Upside: +247.31%
Longeveron
Dec 5, 2024
Initiates: Buy
Price Target: $10
Current: $1.23
Upside: +713.01%